2014
DOI: 10.1016/j.cjca.2014.08.005
|View full text |Cite
|
Sign up to set email alerts
|

Transforming the Promise of Pluripotent Stem Cell-Derived Cardiomyocytes to a Therapy: Challenges and Solutions for Clinical Trials

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
16
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 27 publications
(16 citation statements)
references
References 115 publications
0
16
0
Order By: Relevance
“…Despite the still incomplete understanding of all mechanisms, several groups have independently demonstrated that stem cells can exert a beneficial effect on cardiac function (53,17,16,56,23). However, it is increasingly evident that the role of adult stem cells in cardiac tissue repair is related, at least in part, to the release of a variety of paracrine factors (22,67,14).…”
Section: Figure 1 Biogenesis Of Mirnas and Their Sorting Into Exosomesmentioning
confidence: 99%
“…Despite the still incomplete understanding of all mechanisms, several groups have independently demonstrated that stem cells can exert a beneficial effect on cardiac function (53,17,16,56,23). However, it is increasingly evident that the role of adult stem cells in cardiac tissue repair is related, at least in part, to the release of a variety of paracrine factors (22,67,14).…”
Section: Figure 1 Biogenesis Of Mirnas and Their Sorting Into Exosomesmentioning
confidence: 99%
“…The use of 'deleteriousness'-weighted mutational counts can improve the power of burden-of-mutation studies, further highlighting the importance of better technology for identifying deleterious variants. Application of clustered regularly interspaced short palindromic repeat (CRISPR) technology has enabled (for better or for worse) (Baltimore et al 2015;Bosley et al 2015) germline editing as well as regenerative medicine based on ex vivo engineering of induced pluripotent stem cells (iPSCs) and reintroduction of differentiated cells; however, the functionality of off-target and other passenger mutations still needs to be rigorously examined for safety (Prowse et al 2014;Baltimore et al 2015).…”
mentioning
confidence: 99%
“…In a recent proof-of-principle clinical trial, single-cell, hESC-derived CPCs were embedded in a fibrin gel and implanted onto the epicardium of patients with severe heart failure by positioning the cell-fibrin mixture beneath the pericardial flap [56]. There are also ongoing efforts to gain approval for hPSC-CM clinical trials [16, 57]. …”
Section: Cell Injectionmentioning
confidence: 99%